<DOC>
	<DOCNO>NCT00191607</DOCNO>
	<brief_summary>This trial compare two chemotherapy agent treatment recurrent ovarian , fallopian primary peritoneal cancer patient receive longer respond Platinum base treatment . The purpose trial compare progression free survival gemcitabine liposomal doxorubicin . Progression free survival ( PFS ) define period study entry disease progression</brief_summary>
	<brief_title>A Randomized Trial Patients With Platinum Resistant Ovarian , Fallopian Primary Peritoneal Cancer .</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Peritoneal Neoplasms</mesh_term>
	<mesh_term>Genital Neoplasms , Female</mesh_term>
	<mesh_term>Pelvic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<criteria>All patient must document pathologic diagnosis epithelial ovarian ( FIGO Stage IIV ) , Fallopian tube primary peritoneal carcinoma Patients must receive platinumbased , firstline chemotherapy one additional prior chemotherapy regimen . Patients must recover acute side effect prior chemotherapy prior enrollment trial . Patients must consider platinum resistant disease base recent platinumbased regimen give , i.e. , treatmentfree interval response platinum less six month , progress platinumbased therapy Presence measurable disease CA125 &gt; = 100 two separate occasion least one week apart require study Patient must Zubrod Performance Status 0 , 1 2 Exclusion Patients current diagnosis epithelial ovarian tumor low malignant potential ( borderline carcinoma ) eligible . Patients prior diagnosis low malignant potential tumor surgically resect subsequently develop invasive adenocarcinoma eligible . Patients currently undergo abdominal pelvic radiation therapy patient receive prior abdominal pelvic radiation therapy exclude . Patients unstable angina heart attack within past six month eligible participate . Patients receive prior Gemzar Doxil therapy ineligible .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2007</verification_date>
</DOC>